Last edition
News about "Contract Research Organisation"
Marvel Biosciences Selects Novotech as CRO for MB-204 Phase-I Trial
Marvel Biosciences selects Novotech as CRO for its phase-I clinical trial of MB-204, a patented adenosine A2A antagonist, following successful cGMP synthesis and GLP toxicology studies.
Contract Research Organisation | 25/03/2026 | By News Bureau
Worldwide Clinical Trials Completes Acquisition of Oncology-Focused CRO Catalyst Clinical Research
Worldwide Clinical Trials strengthens its oncology and early-phase research capabilities following the completion of its acquisition of Catalyst Clinical Research.
Contract Research Organisation | 17/02/2026 | By News Bureau | 163
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy